ACS - Acute Coronary Syndrome Clinical Trial
Official title:
Safety and Efficacy of CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection Versus Conventional Antiplatelet Therapy After Complex Percutaneous Coronary Intervention: The PRECISE-PCI Randomized Clinical Trial
In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood "East Asian Paradox", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice.
In the PRECISE-PCI (CYP2C19 Genotype-Guided P2Y12 RECeptor Inhibitor SElection After Complex PCI) trial, the investigators aim to evaluate the safety and efficacy of CYP2C19 genotype-guided P2Y12 receptor inhibitor selection, as compared with conventional therapy in Chinese with ACS undergoing complex PCI All eligible ACS patients will be received DAPT (ticagrelor 180 mg or clopidogrel 300/600 mg plus aspirin 300 mg loading) before PCI. Subsequently to be randomly assigned into the genotype-guided group (CPY2C19 *2 or *3 carrier: ticagrelor 60 mg bid, or 45mg bid if <50 kg, ≥75 years; CPY2C19 *2 or *3 non-carrier: clopidogrel 75 mg qd in combination with aspirin 100 mg qd) and conventional group (ticagrelor 90 mg bid or clopidogrel 75 mg qd in combination with aspirin 100 mg qd). At post-PCI 3 months, both groups will be treated with mono-ticagrelor/clopidogrel without aspirin therapy for a further 9 months. The primary endpoint is focusing on the net adverse clinical events (NACEs, a composite of cardiac death, non-fatal myocardial infarction, target vessel/lesion revascularization, stroke, or BARC-defined clinically significant bleeding type 2, 3, or 5) during 12-month follow-ups. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03273075 -
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
|
Phase 4 | |
| Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
| Recruiting |
NCT04222608 -
The BRAvAdO Registry
|
||
| Recruiting |
NCT06095557 -
MCG Discovery Study in Emergency Departments
|
N/A | |
| Completed |
NCT04000490 -
External Validation of the SCARE Score
|
||
| Recruiting |
NCT04140019 -
Early Cardiac Magnetic Resonance Imaging in Suspected Non-ST-Elevation Myocardial Infarction
|
||
| Completed |
NCT04485754 -
Telemedicine Follow-up for Post-ACS Patients
|
N/A | |
| Completed |
NCT03122184 -
Positive Psychology for Acute Coronary Syndrome Patients
|
N/A | |
| Completed |
NCT03138473 -
Impact of Residual Syntax Score and Syntax Revascularization Index on Outcomes of ACS Patients With Multi-Vessel Disease
|
||
| Completed |
NCT04219761 -
National Tunisian Registry of Percutaneous Coronary Intervention
|
||
| Recruiting |
NCT03707496 -
A Registry of De Winter Symdrome of Single Center
|
||
| Terminated |
NCT04062383 -
Positive Emotions After Acute Coronary Events at Northwestern University
|
N/A | |
| Recruiting |
NCT05378321 -
Prevalence of NAFLD in ACS Patients
|
N/A | |
| Recruiting |
NCT03413410 -
A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome
|
N/A | |
| Completed |
NCT03793582 -
Impact of OSA on Outcomes in Acute Coronary Syndrome
|
||
| Terminated |
NCT05323136 -
Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics
|
Phase 1 |